Citadel Advisors’s Therapix Biosciences Ltd. TRPX Stock Holding History

Citadel Advisors’s Portfolio TRPX Stock Details TRPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,180	Closed	-$4K	–	10860
2020 Q1	$4K	Buy	+10,180	New	+$5.77K	﹤0.01%	9504

Other funds holding TRPX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Citadel Advisors's TRPX Position: Q2 2020 in Review

Citadel Advisors sold out of Therapix Biosciences Ltd. (TRPX) in Q2 2020, closing a stake of 10,180 shares — an estimated $4K sold.

Citadel Advisors first reported a position in TRPX in Q1 2020 and held it in 1 quarter. The position peaked at $4K in Q1 2020. 7 funds tracked by Wall St. Rank hold TRPX as of Q2 2020.

Citadel Advisors reported no remaining Therapix Biosciences Ltd. position as of Q2 2020 after selling out during the quarter.
Citadel Advisors sold 10,180 Therapix Biosciences Ltd. shares in Q2 2020, an estimated $4K.
Citadel Advisors first reported a position in Therapix Biosciences Ltd. in Q1 2020 and held it in 1 quarter.
Citadel Advisors's Therapix Biosciences Ltd. position peaked at $4K in Q1 2020.
7 funds tracked by Wall St. Rank held Therapix Biosciences Ltd. as of Q2 2020.

Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.